Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$12.47 USD
+0.34 (2.80%)
Updated May 20, 2024 04:00 PM ET
After-Market: $12.50 +0.03 (0.24%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ENTA 12.47 +0.34(2.80%)
Will ENTA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ENTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENTA
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
ENTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World
5 Secret Santa Stocks to Pop Surprise Returns
Other News for ENTA
Analysts’ Top Healthcare Picks: OrthoPediatrics (KIDS), Enanta Pharmaceuticals (ENTA)
Buy Rating Affirmed: Enanta Pharmaceuticals’ Clinical and Financial Prospects Bolster Investor Confidence
Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook
Buy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial Execution
Enanta price target lowered by $1 at H.C. Wainwright, here's why